Invivyd (IVVD) Stock
Clinical stage biotech developing immune system treatments. Here's the price, business snapshot, and what's worth knowing about Invivyd in August 2026.
Invivyd Inc (IVVD) is a small‑cap, clinical‑stage biotechnology company (market cap ~US$427M) focused on developing immune‑modulating therapies. The business is centred on research and development, with value driven primarily by clinical milestones, regulatory decisions, licensing deals and potential partnerships rather than steady product revenue. For investors, key considerations include the stage of the pipeline, trial readouts, cash runway and intellectual property. As with many biotech names, share prices can be volatile around clinical data and corporate updates. This summary is educational and not personalised investment advice. Prospective investors should review the company’s regulatory filings, recent investor presentations and clinical data, and consider speaking with a qualified financial adviser. Remember that biotechnology investing carries higher uncertainty: values can rise and fall and past performance is not indicative of future results.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying INVIVYD's stock with a target price of $8, indicating significant potential for growth.
Financial Health
INVIVYD INC is performing well with strong revenue, profit margins, and cash flow per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical‑stage pipeline
Investor attention often centres on trial milestones and data readouts, which can materially affect value; outcomes are uncertain and may be binary.
Scientific approach
The company’s scientific strategy may offer differentiated mechanisms or targets, but early‑stage science carries translational and regulatory risk.
Partnership potential
Successful alliances or licensing can de‑risk development and provide funding, though such deals are not guaranteed and depend on clinical progress.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
